A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
Status:
Completed
Trial end date:
2019-06-05
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study followed by
an open-label treatment phase (OLTP). To evaluate the effect of erenumab (AMG 334) compared
to placebo on the change from baseline in monthly migraine days.